First-in-human phase I dose-escalation study of the oral selective C-met inhibitor EMD 1204831 in patients with advanced solid tumors

Category Primary study
JournalJournal of Clinical Oncology
Year 2012
This article has no abstract
Epistemonikos ID: 25500b9130c4515c841b28b0d82e8d24256c5d1d
First added on: Feb 05, 2025